Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025

Minimizing Cytotoxic Effects on Normal Cells: Enhanced Targeted Delivery of Docetaxel via PCL-PEG-PCL Nanocarriers in Breast Cancer Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAli KhojastehfarAMAmrollah MostafazadehEZEbrahim Zabihi

Discussion

Loading...

Member takes

Overview

Nanoparticle-based drug delivery shows reduced cytotoxicity and enhanced cell death in breast cancer, suggesting improved treatment approaches.

Key Points

  • Nanocarriers significantly reduce cytotoxic effects while enhancing apoptosis in breast cancer cells, particularly MCF-7 and MDA-MB-231.
  • The IC50 values for formulation P1 showed substantial improvement after 72 hours compared to earlier time points.
  • Assessment used high-performance liquid chromatography to evaluate drug release kinetics and encapsulation efficiency.
  • These findings highlight the potential of optimized nanocarriers in minimizing chemotherapy toxicity to normal cells.

Cite This Study

Khojastehfar et al. (2025) studied this question.

synapsesocial.com/papers/69254f97c0ce034ddc359e2ehttps://doi.org/10.22090/jwent.2025.04.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fabrication, characterization and in vitro evaluation of PCL/PVA nanofibers loaded with docetaxel in breast cancer cells2025
  2. 2Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influence of the Nanocarrier Type.2026 · 4 citations
  3. 3Innovative Nanocarrier Strategies for Enhanced Docetaxel Delivery in Cancer Therapy2026
  4. 4Chitosan Nanoparticles of Paclitaxel for the Treatment against MDA-MB-231 Breast Cancer Cells via Oral Nanomedicine: Fabrication and Preclinical Assessment2026
  5. 5Development and Optimisation of Docetaxel-Loaded Polymeric Nanoparticles for Oral Chemotherapy in Breast Cancer2025